Your browser is no longer supported. Please, upgrade your browser.
Athira Pharma, Inc.
Index- P/E- EPS (ttm)- Insider Own0.40% Shs Outstand35.78M Perf Week-1.50%
Market Cap739.14M Forward P/E- EPS next Y-2.09 Insider Trans207.30% Shs Float35.51M Perf Month9.44%
Income- PEG- EPS next Q-0.34 Inst Own70.90% Short Float3.90% Perf Quarter-8.63%
Sales- P/S- EPS this Y-915.40% Inst Trans22.08% Short Ratio4.47 Perf Half Y-24.49%
Book/sh10.15 P/B1.94 EPS next Y-22.00% ROA- Target Price- Perf Year-
Cash/sh8.11 P/C2.43 EPS next 5Y- ROE- 52W Range15.79 - 34.79 Perf YTD-42.48%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-43.14% Beta-
Dividend %- Quick Ratio69.30 Sales past 5Y- Gross Margin- 52W Low25.27% ATR1.31
Employees20 Current Ratio69.30 Sales Q/Q- Oper. Margin- RSI (14)54.15 Volatility8.95% 6.81%
OptionableYes Debt/Eq0.00 EPS Q/Q-50.90% Profit Margin- Rel Volume0.59 Prev Close19.70
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume310.04K Price19.78
Recom1.50 SMA203.20% SMA506.45% SMA200-7.49% Volume60,362 Change0.41%
Oct-13-20Initiated Stifel Buy $36
Oct-13-20Initiated JMP Securities Mkt Outperform $51
Oct-13-20Initiated Jefferies Buy $30
Oct-13-20Initiated Goldman Buy $53
Jun-14-21 07:00AM  
Jun-09-21 07:00AM  
Jun-01-21 07:00AM  
May-26-21 07:00AM  
May-21-21 04:08PM  
May-13-21 04:02PM  
Apr-22-21 12:00PM  
Apr-21-21 07:00AM  
Apr-08-21 07:00AM  
Mar-25-21 04:02PM  
Mar-24-21 07:00AM  
Mar-23-21 07:00AM  
Mar-18-21 01:36AM  
Mar-08-21 07:00AM  
Mar-02-21 07:00AM  
Feb-10-21 04:05PM  
Jan-21-21 05:50PM  
Jan-20-21 07:35PM  
Jan-19-21 07:59AM  
Jan-07-21 07:30AM  
Dec-18-20 09:17PM  
Dec-17-20 11:49PM  
Dec-14-20 07:30AM  
Dec-08-20 07:30AM  
Dec-01-20 07:30AM  
Nov-12-20 04:05PM  
Nov-10-20 07:30AM  
Oct-21-20 07:30AM  
Oct-18-20 11:00AM  
Oct-08-20 07:30AM  
Oct-01-20 07:30AM  
Sep-22-20 04:05PM  
Sep-18-20 12:04PM  
Sep-17-20 08:21PM  
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MILESON GLENNAChief Financial OfficerJun 10Option Exercise1.356,3058,51289,824Jun 10 06:48 PM
CHURCH KEVINVice President of DiscoveryJun 08Option Exercise1.043,1523,27844,133Jun 09 05:39 PM
FLUKE JOHN M JRDirectorFeb 03Option Exercise1.2129,00335,119143,884Feb 04 08:18 PM
PERCEPTIVE ADVISORS LLCDirectorJan 25Buy22.50311,1116,999,9983,425,916Jan 27 05:43 PM